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PURPOSE: Little attention has been paid to the im- 
portance of clinical factors associated with bleed- 
ing complications caused by the use of thrombolyt- 
ic agents. The goal of our study was to examine 
clinical and hematologic factors associated with an 
increased risk of bleeding in a prospectively ob- 
served population that received intravenous tissue 
plasminogen activator for acute myocardial infarc- 
tion. 
PATIEN'ISANDMETHODS: Bleeding complications 
were evaluated in 386 consecutive patients treated 
with 150 mg of tissue plasminogen activator over 
six to eight hours for acute myocardial infarction. 
All patients also underwent immediate cardiac 
catheterization. 
RESULTS: Quantitation of blood loss during the 
patients’ hospital stay included a median drop in 
hematocrit of 11.4 points, a median nadir hemato- 
crit of 31.2, a 14 percent rate of significant clinical- 
ly evident bleeding, and a 31 percent rate of trans- 
fusion of two or more units of blood. All of these 
parameters were much more severe in patients 
treated with coronary artery bypass surgery. Ac- 
cess site hematoma was the most common source of 
bleeding (45 percent of patients), whereas 8 per- 
cent had gastrointestinal bleeding, two patients 
had retroperitoneal bleeding, and two patients had 
intracranial bleeding. The median nadir fibrinogen 
was 1.3 g/liter. Multiple linear regression models 
were used to investigate the relationship between 
clinical variables, including multiple hematologic 
measurements, and measures of the amount of 
blood loss. The use of coronary artery bypass 
grafting was the variable most closely associated 
with hemorrhage. Other invasive procedures (angi- 
oplasty and intra-aortic balloon pumping) were 
also associated with increased bleeding. Among the 
patient descriptors examined, lighter weight, older 
age, female sex, and history of hypertension were 
associated with greater blood loss. Of laboratory 
coagulation parameters, only nadir fibrinogen lev- 
els were significantly associated with more bleed- 
ing. 
CoNcLusIoN: Careful clinical evaluation may im- 
prove assessment of the risk/benefit ratio of 
thrombolytic therapy. 
T he advent of drugs with relative fibrin specificity raised hopes that coronary thrombi could be lysed 
without disturbing the systemic coagulation system 
[l-3]. For this reason, the major impetus to the devel- 
opment of new thrombolytic agents has been the 
search for compounds with greater fibrin specificity. 
Older thrombolytic agents, such as streptokinase and 
urokinase, were known to be associated with signifi- 
cant bleeding complication rates [4,5], at least in part 
due to the systemic lytic state induced by the deple- 
tion of fibrinogen in the systemic circulation [6,7]. 
Early studies with the prototype fibrin-specific agent, 
tissue plasminogen activator (t-PA), suggested that 
although some systemic fibrinogen breakdown oc- 
curred, relative sparing of fibrinogen with a low bleed- 
ing complication rate was observed [8-lo]. 
While attention has focused on the hematologic pa- 
rameters associated with bleeding, few studies have 
examined the importance of clinical factors [ll]. Older 
age has been associated with an increased risk of 
bleeding complications with streptokinase use in one 
study, but this finding has not been replicated because 
no other studies have evaluated this factor [12]. Al- 
though fibrinogen is the most commonly discussed 
measure of the systemic effects of t-PA, other hemato- 
logic factors that can be measured might also affect 
the risk of bleeding. Fibrin(ogen) degradation prod- 
ucts are products of fibrinolysis that possess potent 
anticoagulant and antiplatelet effects. The plasma 
level of t-PA achieved in the blood can now also be 
estimated by accurate and precise assays. The goal of 
this study was to examine clinical and hematologic 
factors associated with an increased risk of bleeding in 
a prospectively observed population treated with in- 
travenous t-PA for acute myocardial infarction. 
PATIENTS AND METHODS 
Patient Population 
A detailed accounting of the patients enrolled in this 
trial has been reported previously [13,14]. Briefly, pa- 
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tients with symptoms of acute myocardial infarction 
of 30 minutes to six hours were included if they had 
ST-segment elevation of at least 0.1 mV in at least two 
contiguous leads of the standard 12-lead electrocar- 
diogram. The usual contraindications to thrombolytic 
therapy, including history or risk factors for serious 
hemorrhage, were observed. Specifically, the following 
factors were considered to be contraindications to en- 
try into the protocol: recent (less than six months) 
trauma, major surgery within two weeks, recent active 
internal bleeding (gastrointestinal or genitourinary), 
structural brain disease including tumor or arteriove- 
nous malformation, uncontrolled hypertension (dia- 
stolic blood pressure greater than 120 mm Hg by sev- 
eral measurements), other serious advanced illnesses 
such as cancer, or prolonged cardiopulmonary resusci- 
tation within two weeks. Patients with a history of 
stroke within six months were excluded, although 
those with a more distant stroke were included in the 
trial. Additionally, patients with age over 75 years, 
previous coronary artery bypass surgery, or cardiogen- 
ic shock on presentation were excluded. A total of 386 
patients were enrolled in the trial from five centers. 
Table I displays the baseline characteristics of the 
entire population. 
t-PA Administration 
All patients were treated with an infusion of pre- 
dominantly single-chain t-PA begun as rapidly as pos- 
sible after informed consent was obtained. In the first 
176 patients, 60 mg was given intravenously over the 
first hour, followed by 20 mg/hour for two hours and 10 
mg/hour over the next five hours. Because of evidence 
from other studies that a weight-adjusted dose might 
be more effective, in the last 210 patients a dose of 1 
mg/kg was given over the first hour, with a maximum 
dose of 90 mg, followed by the remainder of a total 
dose of 150 mg over the next five hours. The clinical 
results of the two dose regimens have been reported 
previously [15]. The weight-adjusted dose was associ- 
ated with less bleeding, whereas patency rates were 
similar with the two regimens. A bolus of 10 percent of 
the first-hour dose was given throughout the study. 
Interventional Strategy 
All patients underwent coronary angiography and 
left ventriculography at 90 minutes after initiation of 
t-PA therapy. Based on the results of this procedure, 
each patient was assigned to one of several groups. If 
the infarct vessel was totally occluded at 90 minutes 
with a significant amount of myocardium remaining in 
jeopardy, immediate angioplasty was attempted. Pa- 
tients with patent infarct vessels and TIM1 (Throm- 
bolysis in Myocardial Infarction) grade 2 or 3 flow 
were assessed in the interventional cardiac catheter- 
ization laboratory for suitability for angioplasty. 
Those who were not suitable underwent triage to the 
Cardiac Care Unit for further pharmacologic therapy. 
In addition, patients in whom cardiogenic shock devel- 
oped after enrollment in the trial were treated with 
angioplasty or surgery at the discretion of the investi- 
gator. Those with ambiguous delineation of the infarct 
artery or less than 50 percent residual stenosis on the 
go-minute angiogram did not undergo immediate an- 
gioplasty. Patients whose infarct arteries were patent 
and suitable for angioplasty were randomly assigned 
to receive either immediate angioplasty or delayed an- 
gioplasty one week later if clinically indicated or soon- 
er if required because of the occurrence of clinically 
significant ischemia. 
All patients were treated with a standardized medi- 
cal regimen after leaving the interventional catheter- 
ization laboratory. Heparin was maintained by contin- 
uous infusion for a minimum of 24 hours to keep the 
activated partial thromboplastin time 1.5 to 2.0 times 
baseline. In patients with residual stenosis greater 
than 50 percent or with a large intimal dissection after 
angioplasty, the heparin was maintained until a final 
decision about further intervention was made (usually 
one week). Aspirin was started either just after treat- 
ment was initiated or just after cardiac catheteriza- 
tion. Aspirin 325 mglday and dipyridamole 75 mg 
three times per day were continued throughout the 
hospitalization. Diltiazem was given in a dose of 30 to 
90 mg four times per day unless contraindicated. Be- 
cause of concern about confounding effects on left 
ventricular function, beta blockers were withheld un- 
less a strong indication (hypertension, angina, or ar- 
rhythmia) necessitated their use. Lidocaine was given 
intravenously for 24 hours as prophylaxis against ven- 
tricular arrhythmias. 
Monitoring included frequent measurement of the 
prothrombin time and activated partial thromboplas- 
tin time (minimum of once daily for the first three 
days). In addition, the hematocrit was measured at 
least once daily for the first three days of treatment 
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and additionally concomitantly with the occurrence of 
a clinical event. 
Severe, recurrent ischemia was defined prospective- 
ly as 20 minutes of ischemic symptoms associated with 
new electrocardiographic ST-segment changes unre- 
sponsive to standard nitroglycerin therapy. Patients 
meeting these criteria returned to the cardiac cathe- 
terization laboratory, where coronary angiography 
was repeated and angioplasty or coronary artery by- 
pass grafting was performed as clinically indicated. 
Retreatment with t-PA was not used. 
Measurement of Hematologic Variables 
T-PA antigen, fibrinogen, and fibrin(ogen) degrada- 
tion products were measured at baseline, three, five, 
eight, and 12 hours after initiation of t-PA therapy. 
Samples were collected in 0.01 M citrate and 1 PM of 
de-Phe-Pro-Arg-Chloromethylketone as previously 
described to avoid in vitro assay artifacts [16]. The 
blood was immediately placed on ice, centrifuged cell- 
free within one hour, and the plasma was stored fro- 
zen. At the time of first thawing, functional assays 
were performed and serum was prepared for fibrin(o- 
gen) degradation product assays. Quantitation of t-PA 
antigen by immunoassay was performed after one ad- 
ditional thawing. The fibrinogen levels were measured 
by both the functional method of Clauss [17] and by 
sulphite precipitation as modified by Vermylen et al 
[18]. Fibrin(ogen) degradation products were mea- 
sured with a hemagglutination inhibition immunoas- 
say [19]. For the measurement of fibrin(ogen) degra- 
dation products, plasma was mixed with an equal 
volume of thrombin and aprotinin for two hours at 
37°C. An enzyme-linked immunosorbent assay based 
on three monoclonal antibodies was used to measure t- 
PA antigen [20]. Plasminogen activator inhibitor ac- 
tivity was measured in baseline samples only via 15 
minute neutralization of exogenously added t-PA as 
described by Verheijen and co-workers [21]. 
Assessment of Bleeding Complications 
Clinical research nurses evaluated the patients on a 
daily basis for overt evidence of bleeding. Emesis and 
stool were checked for the presence of occult blood. 
Serial hematocrits during the hospitalization and at 
the time of discharge were recorded prospectively. Af- 
ter hospital discharge, all charts were reviewed for 
previously unreported episodes of bleeding, and the 
amount of blood products used was tabulated. An esti- 
mate of the net blood loss was calculated by adding the 
number of transfused units of packed red blood cells 
and the admission minus nadir hematocrit divided by 
three [22]. 
Specific sites of bleeding were quantified in the fol- 
lowing manner. Intracranial bleeding was recorded 
when a new neurologic deficit occurred and a cranial 
axial tomographic scan revealed evidence of blood 
density. All patients in the study with new neurologic 
deficits underwent cranial axial tomographic scan- 
ning. The presence of gross blood or a guaiac-positive 
test result in emesis or stool was recorded as gastroin- 
testinal bleeding. A collection of blood in the retroper- 
itoneal space documented by computed tomography 
or surgical exploration was classified as retroperitone- 
al bleeding. 
Bleeding rates were also tabulated using a classifica- 
tion scheme developed in the TIM1 trial [23,24]. In 
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4 = plasminogen activator. 
points is considered “major,” whereas a drop of 10 to 
15 points is considered “minor.” In addition, gross 
hematuria or hematemesis with a drop in hematocrit 
less than 10 points is considered “minor” bleeding. 
Statistical Methods 
The overall amount of bleeding was reported for the 
entire population and for those patients not undergo- 
ing surgery by tabulating the median, 25th, and 75th 
percentiles of nadir and change from baseline to nadir 
(A) hematocrit. Similar statistics were reported for 
blood products used. Cumulative episodes of clinically 
evident bleeding were listed by site, and rates of signif- 
icant bleeding according to the TIM1 criteria were 
tabulated. 
Since no single measure completely captures the 
amount of blood loss, multiple linear regression mod- 
els were developed to examine the relationships 
among clinical baseline characteristics, hematologic 
measurements before and during therapy, interven- 
tional treatment beyond thrombolytic therapy, and 
measures of bleeding. The candidate independent 
variables tested in the models are listed in Table II. 
Measures of bleeding included requirement for two 
units of blood transfusion, nadir hematocrit, A hemat- 
ocrit, and clinically evident episodes of bleeding. The 
results of these models then were compared to estab- 
lish consistent trends among factors associated with 
different measures of bleeding. Because of the explor- 
atory nature of the analyses, an alpha level of less than 
0.10 was used to include a variable in each of the final 
models. 
To demonstrate the relationship between signifi- 
cant variables in the models and clinical outcomes, 
median, 25th, and 75th percentile levels as well as 
means and standard deviations for estimated units of 
blood loss were reported for each level of binary pre- 
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TABLE III TABLE VI 
Bleeding Parameters* Linear Regression Model Results 
All Patients 
(n = 386) 
Non-Operated 
Patients 
(n = 302) 
Nadir hematocrit 
A hematocrit 
t Units lost 
31.2 (27.8-35.3) 32.6 (28.9-36.2) 
-ll.“d‘~--;4 to %O) -lO.“d‘,--;3 to :7.4) 
Units transfused 0 (O-2) 
Mean = 1.76 
Entries are median (25th to 75th percentile). 
t Units transfused + A hematocrit/3 
0 (o-2j 
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Clauss method (g/liter) 1.30 (0.72-1.70) 
Sulphite method (g/liter) 1.50 (1.00-2.02) 
Peak fibrinogen degradation 60 (15-210) 
products &g/ml) 
Baseline plasminogen activator 12 (7-20) 
inhibitor (lU/ml) 
Peak t-PA antigen (rig/ml) 1,430 (900-2,920) 








dictor variables. Scatter plots showing the average 
number of units lost by deciles of the predictor vari- 
able were used to illustrate these relationships for con- 
tinuous variables. 
RESULTS 
As shown in Tables III and IV, bleeding events 
were frequent in the entire population. The median 
drop in hematocrit was 11.4 points with an interquar- 
tile range of -15.4 to -8.0 points. Blood transfusion 
was required in 34 percent of patients, and 31 percent 
required at least two units of packed red blood cell 
transfusions (Table III). Clinically evident bleeding 
was less frequent, observed in 14.2 percent of patients 






Coefficient p Value 
“Major bleed” 
Weight -0.029 0.024 
PA Inhibitor 0.016 0.030 
A hematocrit 
Female gender 1.52 0.069 
Hypertension -1.63 0.019 
Acute PTCA 2.26 0.003 
Late PTCA 1.79 0.056 
IABP 3.25 0.051 
PA Inhibitor 0.03 0.053 
Nadir hematocrit 
-0.13 0.0001 
Female gender -2.59 0.002 
IABP -3.14 0.036 
Weight -0.06 0.007 
Center 2 -1.49 0.026 
Nadir fibrinogen 0.78 0.084 
Units transfused 















PA = plasminogen activator; PTCA = percutaneous transluminal coronary 
angioplasty; IABP = intra-aortic balloon pump: A = change from baseline to 
pre-discharge value. 
TABLE VII 
Profile of Two Patients with Intracranial Bleeding 
Patient 1 Patient 2 
Age 63 74 
Sex Female Female 
Weight (kg) 75 68 
Hypertension Yes No 
Fibrinogen (Clauss) (g/liter) 
Baseline 5.0 4.0 
3 hours 0.48 0.72 
5-8 hours 0.71 0.60 
Fibrin (ogen) degradation products (pg/Tl) 
Baseline 5 
3 hours 770 400 
5-8 hours 400 770 
23 percent of patients had “major” bleeding episodes 
and 24 percent of patients had “minor” bleeding. 
When the 23 percent of patients enrolled in the trial 
who underwent coronary artery bypass grafting were 
removed from the analysis, the amount of blood loss 
was less profound: 16 percent of patients had “major” 
bleeding and 23 percent had “minor” bleeding. 
Table V demonstrates the changes in basic hemato- 
logic parameters in the entire population. A signifi- 
cant depletion of fibrinogen occurred in the majority 
of patients, with 25 percent of patients experiencing a 
drop to a nadir fibrinogen less than 0.7 g/liter (normal 
value: 1.5 to 3.0 g/liter). This decline in fibrinogen was 
accompanied by an elevation in fibrin(ogen) degrada- 
tion products. Baseline plasminogen activator inhibi- 
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tor levels were 12 III/ml, and peak t-PA antigen levels 
rose to 1,430 rig/ml. 
Table VI demonstrates the results of the linear re- 
gression models relating the clinical and treatment 
variables to the bleeding parameters. The influence of 
bypass surgery was so strong that patients treated 
with this procedure were excluded from the models. 
Although some inconsistency between models was ob- 
served, the factors that were most commonly associ- 
ated with increased bleeding risk were invasive proce- 
dures (angioplasty and intra-aortic balloon pumping), 
female sex, smaller size, and older age. These factors 
pertain to both dose groups. Early or previous use of 
aspirin had no discernable effect on bleeding compli- 
cations. The hematologic measurements that were re- 
lated to increased bleeding risk in several of the mod- 
els were the level of fibrinogen depletion measured 
with the Clauss [17] method and the plasminogen acti- 
vator inhibitor levels (at baseline). When surgical pa- 
tients were included in the analysis, the importance of 
the clinical variables remained relatively constant. 
Table VII demonstrates the clinical and fibrinolyt- 
ic profile of the two patients with intracranial bleeding 
in the trial. One of the patients died in-hospital of 
complications arising from the debilitation caused by 
the stroke. The second patient survived the hospital- 
ization. 
Figure 1 demonstrates the relationship between 
baseline patient weight and the estimated number of 
units of blood loss. Lighter patients were at highest 
risk of bleeding. Figure 2 graphically demonstrates 
the relationship between nadir fibrinogen by the 
Clauss [17] method and the summary measure of 
blood loss. Patients with substantial fibrinogen deple- 
tion had a greater amount of blood loss during the 
hospitalization. Figure 3 displays the relationship be- 
tween age and estimated blood loss, demonstrating 
greater blood loss in older patients. 
Figure 4 demonstrates the relationship between bi- 
nary clinical variables and blood loss. Patients who 
underwent surgery, intra-aortic balloon pumping, or 
acute angioplasty had greater blood loss compared 
with patients who did not undergo these procedures. 
Furthermore, patients with a history of hypertension 
and women had a higher risk of bleeding. 
COMMENTS 
The major finding of this study is that evaluation of 
clinical and hematologic factors can lead to improved 
ability to assess the risk of significant hemorrhage in 
patients during treatment with t-PA. The careful ac- 
cumulation of a large data base in a multicenter trial 
has allowed an in-depth examination of this large, het- 
erogeneous population. Confirmation of these results 
in future studies could lead to a re-evaluation of the 
risk/benefit ratio for specific patient subgroups or to 
adjustment of the recommended dosage of thrombo- 
lytic drugs. Whether these relationships are common 
to treatment with all thrombolytic agents or unique to 
t-PA remains a matter of speculation. 
The initial enthusiasm that t-PA therapy would be 
associated with little clinical hemorrhage because of 
its fibrin specificity has proven to be unfounded. Com- 
parison of t-PA and streptokinase in the TIM1 trial 
[11,23] failed to demonstrate a major advantage of 
either with respect to bleeding complications despite 
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Figure 1. Estimated blood loss (number of units transfused plus A 
hematocrit/3) according to deciles of weight. 
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Figure 3. Estimated blood loss (number of units transfused plus A 
hematocrit/3) according to deciles of patient age. 
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Figure 4. Estimated blood loss (number 
of units transfused plus A hematocrit/ 
3) according to selected patient vari- 
ables. * = median; I = interquartile 
range. Hct = hematocrit; CABG = coro- 
nary artery bypass graft: PTCA = percu- 
taneous transluminal coronary angio- 
plasty; HTN = hypertension; IABP = 
intra-aortic balloon pump. 
product accumulation in t-PA-treated patients. The 
European Cooperative Study showed only minor dif- 
ferences in favor of t-PA [25]. The higher than antici- 
pated bleeding complication rates observed after t-PA 
therapy could be attributed to multiple factors. In 
contrast to the early trials using t-PA, the higher doses 
of t-PA in this trial resulted in significant fibrinogen 
depletion. In addition, the use of continuous intrave- 
nous heparin, aspirin, and dipyridamole therapy may 
have enhanced the bleeding risk. Finally, as reflected 
by the results of the various models, the frequent use 
of invasive procedures produced multiple vascular 
hemostatic plugs that were susceptible to lysis by the 
fibrinolytic action of t-PA. 
The amount of bleeding recorded in this trial is com- 
parable to reports of more recent trials using t-PA and 
other thrombolytic agents when immediate cardiac 
catheterization was performed. The TIM1 I trial re- 
ported a 43 to 47 percent incidence of periaccess hema- 
toma and a 22 percent requirement for transfusion 
when transfusions related to procedures (surgery or 
percutaneous transluminal coronary angioplasty) or 
other diseases were exc1ude.d. When all patients were 
included, 29 percent of patients required transfusions 
[24]. The recent TIM1 IA report found that the 
amount of bleeding after t-PA therapy was dose relat- 
ed, but that substantial transfusion rates occurred, 
even when the total dose of t-PA was restricted to 100 
mg [24]. The European Cooperative Study comparing 
streptokinase with t-PA also noted similar bleeding 
complication rates [25]. Large European trials such as 
GISSI [26] and ISAM [27] did not employ early cardi- 
ac catheterization, and thus the degrees of bleeding 
complications are not strictly comparable. Neverthe- 
less, examination of these data confirms that avoiding 
early catheterization substantially reduces bleeding 
risk. 
Previous trials have not examined the specific clini- 
cal factors associated with increased risk of hemor- 
rhage in a large population of patients. The finding of 
increased risk with invasive procedures is not surpris- 
ing, since agents with the ability to lyse a coronary 
thrombus would be expected to produce concomitant 
lysis of vascular hemostatic plugs. This increased risk 
of bleeding with invasive procedures must therefore be 
weighed against the possible benefits of such proce- 
dures both in preventing recurrent ischemia [28,29] 
and in mechanically restoring coronary blood flow 
when thrombolytic therapy fails [30,31]. Importantly 
for the performance of invasive procedures soon after 
thrombolytic therapy, 4 percent of patients required a 
direct repair of the artery. Although this complication 
necessitated an expert vascular surgeon, in no case in 
this trial did permanent disability or loss of limb occur 
as a result of an access site vascular complication. 
Clinical factors should be considered when decisions 
are made about the dose and risk/benefit ratio of 
thrombolytic therapy administration. One previous 
study has found an increased risk of bleeding in elder- 
ly patients treated with intravenous streptokinase 
[ll]. Other clinical factors considered in this study 
have not been specifically evaluated in previous stud- 
ies. The higher risk of bleeding in women and in lighter 
patients may reflect a need to adjust dose according to 
sex and body weight [15]. However, confirmatory 
studies are needed before definitive therapeutic rec- 
ommendations can be made. 
A major problem with studies of bleeding complica- 
tions in the clinical environment is that the amount ,of 
blood loss and the consequences to the patient can be 
difficult to document. The number of transfusions re- 
ceived by the patient is confounded by the differing 
thresholds for transfusion among clinicians and insti- 
tutions. Interpretation of the importance of nadir he- 
matocrit or the change in hematocrit from admission 
to nadir is confounded by the variable frequency of 
sampling and the amount of transfusion. In order to 
compensate for these problems, Landefeld et al [22] 
have proposed the use of a summary measure as used 
in the current study in order to synthesize estimates of 
both blood loss and replacement. The TIM1 trial used 
a similar adjustment [ll]. Objective evidence of the 
amount of blood loss at puncture sites is extremely 
difficult to collect from evaluation of access site hema- 
tomas, because a large amount of blood loss may occur 
in the retroperitoneal space. In addition, widely vari- 
able thigh girth among patients can lead to inability to 
accurately visualize the blood that is present. Despite 
these problems, bleeding remains the major risk of 
thrombolytic therapy, and attempts to better quantify 
this risk in a manner that can be used across different 
studies are mandatory. 
The most serious bleeding complication of thrombo- 
lytic therapy, which frequently results in death or per- 
manent disability, is intracranial bleeding. Both pa- 
tients with this complication in the current study 
conform in some ways to previous reports of high-risk 
patients [32]. Although neither patient had a history 
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or clinical findings compatible with previous stroke or 
structural cerebrovascular disease, both were women, 
one was 63 years old with a history of hypertension, 
and the other was 74 years old. Both patients had 
marked fibrinogen depletion and a large accumulation 
of fibrin degradation products. Additional studies 
with careful evaluation of patients with intracranial 
bleeding are needed to delineate more specifically pa- 
tients in whom thrombolytic therapy should be con- 
traindicated. 
These findings must be tempered by the reduction 
in the recommended dosage of t-PA that has occurred 
since this trial was completed. Because of concern that 
higher doses caused increased bleeding complications, 
and no substantial increase in efficacy, the recom- 
mended dose of t-PA was reduced from 150 mg to 100 
mg. Concern about intracranial hemorrhage rates with 
the higher doses of t-PA were paramount in this rec- 
ommendation [33]. Thus, overall bleeding complica- 
tion rates will decrease, and the relationship of specific 
risk factors to bleeding complications may be some- 
what altered by this reduction in dosage. 
In summary, the use of thrombolytic therapy is as- 
sociated with a trade-off between lysis of coronary 
thrombus for establishment of vessel patency and the 
risk of hemorrhagic complications. Because the action 
of fibrin-specific agents is likely to be the same at the 
site of the coronary thrombus and at the site of extra- 
cardiac vascular hemostatic plugs, a significant risk of 
bleeding will always accompany the therapeutic bene- 
fit of thrombolytic therapy. Patients with increased 
risk of bleeding can be identified, to some extent, by 
evaluation of simple clinical parameters. Our results 
suggest that consideration of dose adjustment may be 
important in women, in older patients, and in lighter 
patients. Little role for intensive monitoring of the 
degree of fibrinogenolysis was found because of the 
weak relationship of these factors to bleeding compli- 
cations. Additional studies are needed to allow better 
identification of patients at increased risk of bleeding. 
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